Drugs / AGX-08
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07602127 | Jul 2026 → Dec 2028 expected | diffuse secondary choroid atrophy | Zhongmou Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGX-08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07602127 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “innovative adeno-associated virus (AAV)-based gene therapy” NCT07602127 ↗ |
| Route | Intravitreal | “Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.” NCT07602127 ↗ |